Skip to main content

Cue Biopharma (NYSE: CUE) — Company Overview, News & Financial Data

Cue Biopharma logo
CUE Cue Biopharma
Cue Biopharma primary media
Company profile

Cue Biopharma

Cue Biopharma (NASDAQ:CUE) is a biopharmaceutical company pioneering the development of a novel class of injectable biologics to selectively engage and modulate target T cells directly within the patient's body. The company's proprietary platform, the Immuno-STAT™ (Selective Targeting and Alteration of T cells) technology, is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation. Cue Biopharma's strategy focuses on creating safer, more effective therapies that can address a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. Their active projects span multiple stages of preclinical and clinical development, aiming to validate the Immuno-STAT platform's versatility and its potential to revolutionize current treatment paradigms by providing targeted, durable, and controllable immune modulation.

Snapshot

Public USOwnership
2014Year founded
52Employees
Boston, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Boston, US

Products and/or services of Cue Biopharma

  • Immunotherapies leveraging Immuno-STAT platform for selective modulation of disease-specific T cells in cancer, autoimmune, and chronic infectious diseases.
  • CUE-101, a biologic engaging and expanding specific anti-tumor T cells in HPV-driven cancers.
  • CUE-102, designed to activate and expand a population of WT1-specific T cells for the treatment of WT1-expressing cancers.
  • CUE-201, aimed at addressing autoimmune diseases by selectively modulating disease-specific T cells without general immune suppression.
  • Biologics for chronic infectious diseases, focusing on leveraging the immune system for durable viral suppression.
  • Partnerships with leading pharmaceutical companies to expand the application of the Immuno-STAT platform across various diseases.

Cue Biopharma executive team

  • Lucinda WarrenPrincipal Accounting Officer & Chief Business Officer
  • Colin G. SandercockSenior Vice President of Intellectual Property
  • Shao-Lee LinPresident, CEO & Director
  • Ronald D. Seidel IIICo-Founder
  • Rodolfo Jose ChaparroCo-Founder
  • Steven C. AlmoCo-Founder and Chairman of Scientific & Clinical Advisory Board
  • James M. AhlersChief Financial Officer
  • Agnes LeeChief Officer of Public & Investor Relations
  • Sumita RayChief Legal & Compliance Officer and Corporate Secretary
  • Daniel G. BakerInterim Chief Development Officer

Recent announcements

What Cue Biopharma (CUE) has told the market, newest first.

  1. LULD halt | CUEPrice sensitive
  2. LULD halt | CUEPrice sensitive
  3. LULD halt | CUEPrice sensitive
  4. LULD halt | CUEPrice sensitive
  5. LULD halt | CUEPrice sensitive
  6. 10-Q | Cue Biopharma, Inc.
  7. 8-K | Cue Biopharma, Inc.
  8. SCHEDULE 13G | Cue Biopharma, Inc.

Key financials

Reported results for Cue Biopharma, in USD.

Market cap
34.7M
Revenue (TTM)
35.6M
P/E ratio
—
EPS (diluted, TTM)
-27.8
Dividend yield
—
Profit margin
0.0%
Cue Biopharma annual revenue and income
Fiscal year endRevenueOperating incomeNet income
27.5M-26.5M-26.6M
9.3M-41.5M-40.7M
5.5M-52.1M-50.7M
1.2M-53.2M-53M